Premium
The effects of bupivacaine and pipecoloxylidide on platelet function in vitro
Author(s) -
Odoom J. A.,
Sturk A.,
Dokter P. W. C.,
Bovill J. G.,
Cate J. W. ten,
Oosting J.
Publication year - 1989
Publication title -
acta anaesthesiologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.738
H-Index - 107
eISSN - 1399-6576
pISSN - 0001-5172
DOI - 10.1111/j.1399-6576.1989.tb02928.x
Subject(s) - bupivacaine , medicine , platelet , metabolite , platelet aggregation , in vitro , anesthesia , beta thromboglobulin , platelet rich plasma , pharmacology , endocrinology , platelet activation , biochemistry , biology
The influence of bupivacaine and its major metabolite, pipecoloxylidide, on human platelet function was studied in vitro . Significant inhibition of ADP and collagen‐induced platelet aggregation occurred only with concentrations of bupivacaine above 10 μg · ml ‐1 . This concentration (10–25 μg · ml ‐1 ) is much higher than would be expected in routine clinical use of bupivacaine for epidural analgesia. The inhibition of platelet aggregation was associated with a significant decrease in β‐thromboglobulin secretion. In contrast, pipecoloxylidide had no effect on platelet aggregation or the β‐thromboglobulin release. We conclude that the previously reported 30‐min time‐lag between the maximal plasma concentration of bupivacaine and the inhibition of platelet aggregation is unlikely to be due to a metabolism of bupivacaine to pipecoloxylidide.